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Abstract: The aim of this study was to evaluate the correlation between circulating tumor 
cells (CTCs) and patterns of recurrence in patients with hormone-sensitive prostate cancer. The 
study involved patients with histologically confirmed, advanced prostatic adenocarcinoma, who 
were tested for CTCs (Veridex®) when they developed recurrence after radical prostatectomy 
or external beam radiation between 2008 and 2014. Forty-two prostate cancer patients were 
evaluated. CTCs were detected in 14 out of 42 (33.3%) patients (Group A), while the remaining 
28 (66.7%) showed undetectable levels of CTCs (Group B). The mean prostate-specific antigen 
value was higher in Group A in comparison to Group B (6.2 vs 3.3 ng/dL) (P=0.48). Presence of 
bone metastases alone or along with nodal metastases was more common in Group A (57.1%) 
in comparison to Group B (25%) (P=0.04). In a univariate analysis, the presence of CTCs 
at diagnosis correlated with the development of bone recurrence (OR: 4; 95% CI: 1.0–15.9; 
P=0.05). Even if the study enrolled only a small number of patients, the detection of CTCs in 
the blood appears to correlate with the pattern of progression in patients with hormone-sensitive 
prostate cancer, suggesting a possible role in anticipating recurrence at the bone in men with 
higher tumor load. Further prospective studies are warranted in this setting.
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Introduction
Prostate cancer is the second leading cause of cancer-related deaths in men in most 
Western countries, and the optimal strategy of treatment in early disease includes radical 
prostatectomy.1 However, external beam radiation therapy is sometimes preferred, as 
it is associated with a reduction in both early and late complications.2 Unfortunately, 
the 20%–40% of patients undergoing radical prostatectomy1,2 and the 30%–50% of 
patients undergoing radiotherapy (RT) experience recurrence within 10 years.3 In this 
setting, clinical and histopathological factors, such as baseline prostate-specific anti-
gen (PSA) levels, pathologic tumor and lymph node stage, Gleason score, surgery 
and PSA doubling time have been evaluated for their prognostic and predictive role.4 
However, the identification of patients with high risk of local and/or distant recurrence 
still remains difficult, and new predictive biomarkers are needed. High-risk prostate 
cancer patients undergoing treatment often experience biochemical recurrence, also 
apart from developing bone metastases, with related clinical complications and a 
decline in the quality of life. In this setting, it is reported that the use of adjuvant bis-
phosphonates may help in delaying tumor-related skeletal events.5 Close monitoring 
of patients and the identification of new predictive markers of recurrence could benefit 
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patients who may need further adjuvant treatment to prevent 
bone metastases and the associated complications.
Circulating tumor cells (CTCs) are cancer cells detectable 
in the peripheral blood after probably being released by the 
tumor. CTCs showed prognostic significance either before 
or during systemic therapy in prostate cancer.6 Moreover, 
in patients with metastatic disease, the presence of CTCs 
correlates with decreased overall survival.7,8 Finally, it has 
been shown that CTCs also predict responsiveness to hor-
monal therapy or chemotherapy in patients with prostate 
cancer.8,9 However, very few data are available on the cor-
relation between CTC positivity and patterns of recurrence 
in patients with hormone-sensitive prostate cancer. The aim 
of this study was to investigate the presence of a correlation 
between CTC positivity and risk of recurrence in patients 
with hormone-sensitive prostate cancer.
Patients and methods
eligibility criteria
This study involved patients with histologically confirmed, 
advanced prostatic adenocarcinoma treated at the Radio-
therapy Department, Azienda Socio – Sanitaria Territoriale 
di Cremona, Italy, who showed recurrence after radical 
prostatectomy or external beam radiation therapy between 
2008 and 2014. Hormone therapy and whole-pelvis radia-
tion were used at the discretion of the treating physician. 
Patients who received adjuvant RT (initiated ,6 months 
after radical prostatectomy) were included. Prior adjuvant 
hormonal therapy was allowed if the duration of therapy 
was #24 months and progression had occurred .12 months 
after completion of therapy.
Follow-up and definition of outcome
Follow-up after primary treatment included medical 
examination and PSA dosage every 3 months for the first 
2 years and every 6 months after 2 years. Biochemical 
failure was defined as an increase of PSA $0.2 ng/mL at 
least twice, as per American Urological Association (AUA) 
recommendation;10 PSA rise .2 ng/mL11 for patients who 
underwent RT; and PSA doubling time ,6 months.12 During 
recurrence, diagnostic imaging was performed, including 
computed tomography (CT), positron emission tomography 
(PET)/CT or bone scan, at the discretion of the treating 
physician. Metastatic disease was defined by the presence of 
bone and/or soft tissue involvement. A clinical database was 
established, which contained patient characteristics, tumor 
grading according to Gleason score and follow-up details, 
including PSA concentrations.
ethical approval
All procedures were performed according to the ethical 
standards of the institutional research committee and with 
the Declaration of Helsinki 1964 and later amendments or 
comparable ethical standards. The study was approved by the 
Ethics Committee of Azienda Socio – Sanitaria Territoriale 
di Cremona. Informed written consent was obtained from all 
participants included in this study.
cTc isolation method
A peripheral blood sample was collected for the evaluation 
of CTCs. Isolation and enumeration of CTCs was performed 
using Veridex CellSearch® assay. For CTCs enumeration, 
20 mL of whole blood was drawn into two proprietary 
CellSave tubes (Veridex). CTC positivity was defined 
as $5 CTCs/7.5 mL. After immunomagnetic capture, the 
CTCs were labeled with a fluorescent nucleic acid dye, 
4′,6-diamidino-2-phenylindole. The identification and 
quantification of CTCs was performed by the CellTracks 
Analyzer II, a semiautomated fluorescence microscope 
that enables computer-generated reconstruction of cellular 
images. CTCs are defined as nucleated cells expressing 
cytokeratins (CKs) 8, 18 and 19 and lacking CD45.
statistical considerations
The aim of this study was to evaluate whether CTCs correlate 
with patterns of recurrence in patients with hormone-sensitive 
prostate cancer. The CellSearch detection assay, is approved 
by the US Food and Drug Administration and was used for the 
counting of CTCs.6 For trial purposes, patients were divided 
into two groups: group A containing patients with positive 
CTC result ($5 CTCs/7.5 mL) and group B having patients 
with negative CTC samples (,5 CTCs/7.5 mL).
For statistical analysis purposes, a preliminary data 
exploration was performed. Numerical variables were 
expressed as median and range, and these were compared 
using nonparametric tests (Mann–Whitney U-test). Qualita-
tive data were expressed as frequencies and organized into 
contingency tables; the association between categorical 
variables was investigated by means of the Fisher’s exact 
test or Person’s chi-square. Time-dependent variables were 
calculated according to the Kaplan–Meier method. Logistic 
regression analysis was done to identify the applicability of 
positive CTC results in the prediction of metastatic recur-
rence. For the entire statistical analysis, the significance level 
was established at P,0.05. All data were analyzed using 
STATA software.
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Results
Patient characteristics
From September 2008 to June 2014, peripheral blood samples 
of 42 prostate cancer patients with recurrence after primary 
treatment were analyzed. CTCs were detected in 14 patients 
out of 42 (33.3%, Group A), while these were undetectable 
in the remaining 28 patients (66.7%, Group B) (Figure 1). 
The characteristics of the 42 enrolled patients are shown in 
Table 1. The median age was 65 years (63 and 66 years in 
the groups A and B, respectively). There was no statisti-
cally significant difference in the type of primary treatment 
between the two groups. Moreover, 8 patients (57.1%) in 
Group A and 8 (28.5%) in Group B had a Gleason score $8.
correlation data
At the median follow-up of 56 months, all patients were 
alive. The median time to recurrence was 32 months 
(95% CI: 14–42 months) in Group A and 40 months 
(95% CI: 12–72 months) in Group B (P=0.6) (Table 2). The 
mean value for PSA was 4.3 ng/mL, with a nonsignificant, 
higher value in Group A in comparison to that in Group B 
(6.2 vs 3.3 ng/dL; P=0.48). The main site of recurrence was 
the bone (39.5%).
Table 3 reports the data on the correlation among primary 
treatment, Gleason score and sites of recurrence per group. 
No statistically significant difference was observed between 
groups A and B in terms of primary treatment (P=0.25) or 
Gleason score (P=0.07). Bone metastases alone or associ-
ated with nodal metastases were more frequent in Group A 
(57.1%) in comparison to that in Group B (25%) (P=0.04). 
Moreover, 5 patients (35.7%) had local recurrence and 
1 patient (7.1%) had biochemical failure in Group A, but no 
nodal recurrence was seen. In Group B, 9 patients (32.1%) 
had local recurrence; 6 (21.4%) had biochemical failure 
and 6 (21.4%) had nodal recurrence. In univariate analysis 
of the logistic regression model, the presence of CTCs was 
statistically correlated with the development of bone metas-
tases (OR =4.0; 95% CI: 1.0–15.9; P=0.05) but not with 
biochemical recurrence (OR =0.28; 95% CI: 0.32–2.61; 
P=0.3). Although lacking statistical significance, a correla-
tion was found between presence of CTCs and development 
of local recurrence (OR =1.17; 95% CI: 0.30–4.52; P=0.8). 
Finally, correlation between CTC positivity and nodal recur-
rence was not analyzed due to the absence of cases of nodal 
recurrence in Group A.
Discussion
Several studies showed the prognostic role of CTCs in 
patients with metastatic castration-resistant prostate cancer 
(mCRPC).6,7 Recently, data from .263 evaluable patients with 
mCRPC enrolled in a Phase 3 trial (SWOG S0421) showed 
that detection of CTCs at baseline (pretreatment) is a strong 
prognostic marker during chemotherapy with docetaxel.14 In 
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Figure 1 Occurrence of cTcs.
Note: red bars indicate the cTc-positive patients; blue bars indicate the cTc-
negative patients.
Abbreviation: cTc, circulating tumor cell.
Table 1 Patient characteristics
Characteristics of 
enrolled patients
Overall Group A Group B
N=42  n=14  n=28
Median age, years 65 63 66
Median Psa values at diagnosis
#10 ng/ml 34 9 25
.10 ng/ml 8 5 3
gleason grade
,8 26 6 20
$8 16 8 8
Primary treatment
radical prostatectomy 13 5 8
radiotherapy 14 5 9
Both 15 4 11
lh-rh therapy 18 9 9
Mean Psa values at 
recurrence, ng/ml
4.3 6.2 3.3
site of recurrence
Biochemical failure 7 1 6
Prostate 14 5 9
nodal 6 0 6
Bone + nodal 3 1 2
Bone only 12 7 5
Notes: group a: cTc-positive patients. group B: cTc-negative patients.
Abbreviations: cTc, circulating tumor cell; lh-rh, luteinizing hormone-releasing 
hormone; PSA, prostate-specific antigen.
Table 2 numerical variables according to group differences
Variables Group A Group B P-value
Median age, years (range) 63 (45–84) 66 (44–86) 0.7
Median time to first 
recurrence, months (95% ci)
32 (18–42) 40 (12–72) 0.6
Mean Psa values at 
recurrence, ng/ml (range)
6.2 (0.2–18.6) 3.3 (0.2–15.8) 0.5
Notes: group a: cTc-positive patients. group B: cTc-negative patients.
Abbreviations: CTC, circulating tumor cell; PSA, prostate-specific antigen.
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addition, Scher et al evaluated the role of CTCs in mCRPC 
patients enrolled in the COU-AA-301 Phase 3 trial.13 The 
trial compared abiraterone plus prednisolone to placebo plus 
prednisolone in patients who progressed after docetaxel. 
Although CTCs alone failed to show a prognostic significance, 
the combination of CTCs and lactate dehydrogenase (LDH) 
levels at 12 weeks showed a prognostic role and met all sur-
rogacy criteria for survival. In accordance with these findings, 
we confirmed a predictive role of CTCs in patients with recur-
rent prostate cancer. In fact, the subgroup of patients with a 
positive CTC count at baseline had a higher PSA mean value 
at recurrence and higher Gleason score in comparison to men 
with undetectable CTCs. Positive CTC status at baseline was 
also associated with shorter disease-free survival (DFS; Tables 2 
and 3). It is well known that not all patients with recurrent 
prostate cancer have the same prognosis. Thus, it is important 
to identify not only patients at “high risk” of recurrence but 
also the type of recurrence most likely to occur, namely, local 
or distant. In this context, several factors have been investi-
gated to evaluate the risk of recurrence,15,16 but none of these 
potential factors has demonstrated reliability as predictor of 
bone metastases. Our results suggest that CTCs may be helpful 
in identifying a subgroup of patients who are at high risk of 
developing bone metastases.
However, we report some important limitations to 
our approach: the small sample size precludes definitive 
conclusions; furthermore, our patients received different 
primary treatments (RT, surgery or both); and finally our 
study is a retrospective study, with its related intrinsic limita-
tions and risk of bias.
Conclusion
Despite the small number of patients, the significant associa-
tion between the presence of CTCs and tumor recurrence in 
the bone in patients with hormone-sensitive prostate cancer 
supports the hypothesis that CTCs may be considered a 
predictive marker of recurrence. However, further prospec-
tive studies with larger numbers of patients are required to 
confirm our results.
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Table 3 categorical variables according to group differences
Variable Categories Group A, 
n (%)
Group B, 
n (%)
P-value
Primary 
treatment
radical prostatectomy 5 (35.7) 8 (28.5) 0.25
radiotherapy 5 (35.7) 9 (32.1)
Both 4 (28.5) 11 (39.2)
sites of 
recurrence
Bone 8 (57.1) 7 (25) 0.04
non-bone 6 (42.8) 21 (75)
gleason score ,8 6 (42.8) 20 (71.4) 0.07
$8 8 (57.1) 8 (28.5)
Notes: group a: cTc-positive patients. group B: cTc-negative patients. 
Statistically significant value is shown in bold. 
Abbreviation: cTc, circulating tumor cell.
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